Russell Investments Group Ltd. Boosts Stock Holdings in Axon Enterprise, Inc $AXON

Russell Investments Group Ltd. lifted its position in Axon Enterprise, Inc (NASDAQ:AXON) by 38.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145,209 shares of the biotechnology company’s stock after acquiring an additional 40,214 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.18% of Axon Enterprise worth $79,947,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Axon Enterprise by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after purchasing an additional 53,060 shares in the last quarter. Geode Capital Management LLC grew its position in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after purchasing an additional 35,544 shares in the last quarter. Sands Capital Management LLC increased its stake in Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after buying an additional 167,095 shares during the last quarter. Wellington Management Group LLP increased its stake in Axon Enterprise by 326.9% in the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after buying an additional 1,179,038 shares during the last quarter. Finally, Edgewood Management LLC bought a new position in shares of Axon Enterprise during the 4th quarter worth approximately $846,516,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Northland Securities raised several future earnings estimates. The firm lifted its FY2027 EPS forecast to $6.49 from $5.53 and increased estimates for Q1–Q4 2027, as well as Q3 2026. The revisions suggest stronger anticipated earnings from Axon’s connected-device, software, AI and public-safety technology businesses.
• Positive Sentiment: Axon raised its 2026 revenue-growth outlook to 32%–34%. Management cited strong momentum in connected devices, international demand, counter-drone products and AI-enabled software, supported by approximately $15.1 billion in future contracted bookings. Axon Enterprise Is Up 17.8% After Raising 2026 Revenue Outlook
• Neutral Sentiment: Recent quarterly results exceeded expectations. Second-quarter revenue increased 35.3% year over year to $904.4 million and topped consensus, while adjusted EPS also beat estimates. However, reported net income and diluted EPS declined, highlighting the trade-off between rapid expansion and near-term profitability. The 5 Most Interesting Analyst Questions From Axon’s Q2 Earnings Call
• Negative Sentiment: Northland reduced its FY2026 EPS forecast to $3.12 from $3.26 and cut its Q4 2026 estimate to $1.29 from $1.55. These downgrades indicate some near-term earnings pressure even though longer-term forecasts improved.
• Negative Sentiment: Insider selling added pressure. A report attributed a 6.5% decline to recent insider sales, which can raise concerns about valuation or management’s view of near-term upside. Axon Enterprise Trading Down Following Insider Selling
• Negative Sentiment: Valuation and margins remain risks. With a very high earnings multiple and reported margin contraction, investors may be demanding clearer evidence that revenue growth will translate into sustained profit growth.

Insiders Place Their Bets

In related news, CEO Patrick W. Smith sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $10,000,000.00. Following the transaction, the chief executive officer owned 3,060,997 shares in the company, valued at approximately $1,530,498,500. This represents a 0.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total value of $753,690.00. Following the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 68,989 shares of company stock valued at $36,016,932 in the last quarter. 4.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group restated a “buy” rating and issued a $715.00 target price on shares of Axon Enterprise in a research note on Thursday, August 6th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. Barclays lifted their price target on Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. boosted their price objective on Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $700.00 price objective on shares of Axon Enterprise in a research note on Thursday, June 25th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $730.92.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $612.83 on Friday. The firm has a market cap of $49.79 billion, a price-to-earnings ratio of 254.29, a P/E/G ratio of 12.50 and a beta of 1.39. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $794.29. The firm’s 50-day simple moving average is $526.06 and its two-hundred day simple moving average is $474.40.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm had revenue of $904.39 million during the quarter, compared to the consensus estimate of $876.42 million. During the same period in the prior year, the firm earned $2.12 EPS. The company’s revenue was up 35.3% compared to the same quarter last year. As a group, equities analysts forecast that Axon Enterprise, Inc will post 2.04 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.